Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LGVN Longeveron
4.040+0.048+1.20%
Close
02/03 16:00 ET
4.0400.0000.00%
Post Mkt Price 02/03 18:55 ET
High
4.180
Open
4.050
Turnover
146.90K
Low
3.930
Pre Close
3.992
Volume
36.08K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Head to Head Comparison: VG Life Sciences (OTCMKTS:VGLS) Vs. Longeveron (NASDAQ:LGVN)
Longeveron (NASDAQ:LGVN – Get Rating) and VG Life Sciences (OTCMKTS:VGLS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses bas
Longeveron (NASDAQ:LGVN) Vs. VG Life Sciences (OTCMKTS:VGLS) Head to Head Review
VG Life Sciences (OTCMKTS:VGLS – Get Rating) and Longeveron (NASDAQ:LGVN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on
Watching Longeveron; Zacks Small-Cap Research Gives $20 Price Valuation
Watching Longeveron; Zacks Small-Cap Research Gives $20 Price Valuation
Longeveron Highlights Publication Of Final Data From ELPIS I Trial Of Lomecel-BTM
-- Full results published in European Heart Journal Open ---- Study met primary safety endpoint ---- All patients alive, transplant-free, and maintained expected rate of growth one year after treatmen
Longeveron Announces Publication of Final Data From ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment --
Maxim Group Sticks to Its Buy Rating for Longeveron (LGVN)
EF Hutton Adjusts Longeveron Price Target to $12.50 From $20, Maintains Buy Rating
07:51 AM EST, 01/10/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
EF Hutton Sticks to Their Buy Rating for Longeveron (LGVN)
Longeveron Price Target Cut to $12.50/Share From $20.00 by EF Hutton
Longeveron Is Maintained at Buy by EF Hutton
Company Overview
More
Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.
CEO： Mr. Geoff Green
Market： NASDAQ
Listing Date： 02/12/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet